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Cyclosporine A up-regulates angiotensin II receptors and cal- tion and autoimmune diseases [1, 2]. However, its clinical
cium responses in human vascular smooth muscle cells. use is limited because of its nephrotoxicity and ability
Background. The most widely used immunosuppressive drug to induce hypertension [3–5], and there is evidence thatfor preventing graft rejection and treating autoimmune dis-
increased vasoconstriction is responsible for both sideeases is currently cyclosporine A (CsA). However, CsA also
effects [6–9]. The renin-angiotensin system is one of thecauses vasoconstriction, which is considered to be at the origin
of CsA-induced nephrotoxicity and hypertension. To evaluate most important systems regulating blood vessel tone and
the cellular basis for these side effects, we studied the influence is also known to play a key role in the development of
of CsA on the regulation of the free cytosolic Ca21 concentra- some forms of arterial hypertension [10]. For example,tion ([Ca21]c) in cultured human vascular smooth muscle cells
angiotensin II (Ang II) receptor density in kidneys of(SMCs).
spontaneously hypertensive rats is significantly higherMethods. SMCs were isolated from the medial layer of hu-
man aorta. [Ca21]c regulation was studied by fluorimetry with than in control rats [11, 12]. In addition, the increased
fura 2 and by measuring 45Ca21 effluxes. Angiotensin II (Ang expression of the Ang II type 1A receptor (AT1A) geneII) receptors were detected by [125I]Ang II binding.
contributes to glucocorticoid-induced hypertension inResults. Pretreatment of human SMCs for 24 hours with
rats [13]. In CsA-induced hypertension, an elevation ofCsA in its therapeutic concentration range (0.1 to 10.0 mm)
had no effect on basal [Ca21]c, but increased the [Ca21]c eleva- AT1A receptors in aortic smooth muscle cells (SMCs) has
tion and 45Ca21 efflux when cells were stimulated with Ang II. been demonstrated [14]. Using isolated rat aortic SMCs,
Half-maximal effects occurred at approximately 1 mm CsA. we previously demonstrated that CsA augments vaso-
The CsA effects on [Ca21]c were accompanied by a nearly constrictor hormone-induced elevation of free cytosolictwofold increase in Ang II receptor number, whereas no change
Ca21 concentration ([Ca21]c) and 45Ca21 effluxes [15, 16].in affinity to Ang II was observed. CsA did not alter endothelin-
1- or thapsigargin-induced 45Ca21 efflux. Increases in both Ca21 The aims of this work were to evaluate whether CsA
responses and [125I]Ang II binding were attenuated by the tran- affects vasoconstrictor hormone-dependent [Ca21]c regu-
scriptional inhibitor actinomycin D. The effects of CsA did lation in human cells in order to evaluate if these obser-not appear to be mediated by calcineurin inhibition because
vations are also valid in humans, and to determine whichcyclosporine H, which is not immunosuppressive, also in-
mechanisms could be involved. In this study, we demon-creased the Ang II-induced 45Ca21 efflux.
Conclusion. These data suggest that CsA preferentially up- strate that CsA augments Ang II-induced Ca21 responses
regulates the transcription of Ang II receptors, which very and elevates Ang II receptor density in cultured SMCs
likely leads to vasoconstriction in vivo and could be at the origin isolated from human aorta. These effects do not appearof CsA-induced hypertension and nephrotoxicity in humans.
to be related to the immunosuppressive activity of CsA.
Cyclosporine A (CsA) is currently the most widely METHODS
used immunosuppressive drug for preventing graft rejec- Chemicals and buffers
Cyclosporines A and H were gifts from Novartis
Pharma (Basel, Switzerland). [Arg8]vasopressin, Ang II,Key words: Ang II, CsA, nephrotoxicity, vasoconstriction, cytoplasmic
calcium, smooth muscle cells, hypertension. and endothelin-1 (ET-1) were obtained from Bachem
Feinchemikalien AG (Bubendorf, Switzerland). Thapsi-Received for publication August 27, 1998
gargin was from Sigma Chemie AG (Buchs, Switzer-and in revised form December 31, 1998
Accepted for publication January 5, 1999 land). Fura 2/AM was from Molecular Probes (Eugene,
OR, USA), and 45Ca21 (10 to 40 mCi/mg calcium) was 1999 by the International Society of Nephrology
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from Amersham International (Little Chalfont, Buck- 1 mCi of 45Ca21 per well for 15 minutes at 378C. Then
the cells were washed rapidly four times with ice-coldinghamshire, UK). All chemicals used were of the purest
grade available. Stock solutions of CsA and analogues PSS/1.2 mm CaCl2, and 45Ca21 efflux was initiated by
incubating them at 378C in PSS/1.2 mm CaCl2 (0.5 ml perwere prepared at a concentration of 1022 m in ethanol,
and peptide hormones were in 0.1 mm acetic acid. At well). After three, six, and nine minutes, the supernatants
were removed and immediately replaced by 0.5 ml ofmost, 0.1% of EtOH was present in the assays, and
as tested, this did not affect the calcium response. The fresh PSS/1.2 mm CaCl2 at 378C. Agonists were added
in this buffer at the ninth minute. For the determinationcomposition of physiological salt solution (PSS) solution
was (in mm): 145 NaCl, 5 KCl, 5 HEPES, 1 MgCl2, 10 of the agonist effects, the supernatant was removed at
the 11th minute. Cellular 45Ca21 content was determinedglucose, pH 7.4, with either 1.2 or 0.12 mm CaCl2.
by detaching the cells with 50 ml of a solution of trypsin/
Culture of human smooth muscle cells EDTA (0.25/1%) in PSS followed by an addition of 250
ml of a 1% sodium dodecyl sulfate (SDS) solution. TheSmooth muscle cells were isolated from thoracic seg-
ments of human aortas from 14- to 25-year-old men six radioactivity of the supernatants and of the lysate was
measured by liquid scintillation counting (Packard Trito eight hours after sudden death, which is in agreement
with ethical rules as previously described [17]. For the Carb 4640).
Results are expressed as the fraction of counts perresults described here, the medial layer of a vessel from
a 14-year-old boy was used for the initial culture; qualita- minute in the supernatant versus total cell-associated
counts per minute (in cpm/min per well) as described [16].tively similar results were also obtained with another
human SMC preparation. Briefly, the vessels were
Measurement of [Ca21]copened lengthwise under aseptic conditions. Adventitia
were removed mechanically. The vessels were washed For [Ca21]c measurements, the cells were grown as
described earlier in this article on rectangular coverslipswith PBS, and segments were cut under sterile condi-
tions. The media was separated mechanically from the (22.0 3 10.5 mm) pretreated with 0.2% gelatin. After
reaching confluence, serum-free DMEM was added, andintima along the internal elastic lamina. The pieces of
media were treated with protease solution (0.225% colla- the cells were incubated with CsA for 20 to 24 hours.
They were washed with DMEM and incubated ingenase and 0.05% elastase) for three hours at 378C. After
washing by low-speed centrifugation, the cells were DMEM containing 5 mm of fura 2/AM for 30 minutes
at 378C. [Ca21]c measurement was performed on a dual-seeded at a density of 3 to 5 3 104 cells/cm2 into culture
dishes pretreated with 0.2% gelatin. SMCs were cultured beam spectrofluorometer (Spex Fluorolog) as described
[18]. The coverslip with the cells was placed at an anglein Dulbecco’s modified Eagle’s medium (DMEM) with
20% of heat-inactivated human serum maintained at of 458 in a holder inside a 1 3 1 cm quartz cuvette.
Fluorescence was excited at 340 and 380 nm, and emis-378C in an atmosphere of 95% air/5% CO2, with medium
changes every third day. Cells were identified by mor- sion was measured at 510 nm. Calibrations were per-
formed by treating the cells with ionomycin (1025 m)phological evaluation as typical SMCs; 50 to 75% of
them showed positive staining for smooth muscle-spe- followed by 5 mm CaCl2 to obtain the maximal signal
and by the addition of ethylene glycol aminoethyl ethercific actin. The remainder were also of smooth muscle
type but not sufficiently differentiated. When the cells tetraacetic acid (EGTA) (10 mm) to get the minimal
signal. Background fluorescence, obtained by quenchinghad grown to confluence, they were trypsinized in PBS
[0.05% trypsin, 0.02% ethylenediaminetetraacetic acid the fura 2 fluorescence with MnCl2 (1 mm), was sub-
tracted.(EDTA)] and seeded at a density of 3 to 4 3 104 cells/
cm2. Cells were used from passages 7 to 11.
[125I]Angiotensin II binding
Pretreatment with compounds The cells cultured in 24-well plates were washed twice
with 0.5 ml PSS/1.2 mm CaCl2 (208C), and 0.2 ml ofTo study the effects of CsA or other compounds, the
culture medium was removed. Cells were washed with an [125I]Ang II (1.5 to 3.0 3 104 dpm; specific activity 2200
Ci/mmol; NEN Life Science, Boston, MA, USA) in PSSequal volume of DMEM without serum, and appropriate
agents diluted from a 1022 m stock solution (in ethanol) containing 0.1% gelatin and 0.01% bacitracin were
added together with various concentrations of unlabeledwere added. In control experiments, a solution of ethanol
(0.1%) in DMEM was added to cells. Ang II. Binding was allowed to occur during 20 minutes
at 208C. Wells were washed four times with 0.5 ml of
45Ca21 efflux experiments ice-cold PSS/1.2 mm CaCl2. The liquid was carefully aspi-
rated, and 0.2 ml of 1 n NaOH was added to each wellFor 45Ca21 loading, cells were washed twice with physi-
ological salt solution containing 0.12 mm CaCl2 (PSS/0.12 to disrupt the cells. Radioactivity of the samples was
measured in a g-counter (Gamma Master; Pharmacia,mm CaCl2) and were incubated in this buffer containing
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Fig. 1. Effects of cyclosporine A (CsA) on free cytoplasmic calcium concentration ([Ca21]c) (A) and on Ang II-induced [Ca21]c increments over
basal level (B) in human smooth muscle cells (SMCs). Cells were pretreated in the presence of 1 and 10 mm CsA or 0.1% ethanol (control, CT)
during 24 hours. The results shown in (A) are representative of five to eight experiments. Lines are: (solid line) CsA 10 mm; (long dash) control;
(short dash) CsA 1 mm; bars represent the means 6 sem. *P , 0.05; **P , 0.01.
Uppsala, Sweden). Total binding was measured with a from basal to Ang II-stimulated 45Ca21 efflux increased
almost threefold (from 1.54% in control cells to 4.22%final Ang II concentration of 1.2 3 10210 m and nonspe-
cific binding with 1025 m Ang II. To determine the bind- in CsA-treated cells; Table 1). Basal 45Ca21 efflux was
not affected by CsA (Table 1).ing constants (KD and Bmax) of the receptors, Ang II
concentration was varied between 10210 and 1028 m. Spe- To determine the sensitivity of human SMCs toward
CsA, 45Ca21 efflux measurements were performed. Cellscific binding was calculated as the difference between
total and nonspecific binding, and it amounted to approx- were pretreated with different CsA concentrations dur-
ing 24 hours. The resulting effects on the Ang II-inducedimately 20%. The amount of bound [125I]Ang II was
expressed in fmol/mg protein. Total protein was mea- increases in 45Ca21 efflux over basal are shown in Figure
2. Already at a concentration of 0.1 mm, CsA significantlysured by the method of Bradford [19].
elevated the increase in 45Ca21 efflux due to Ang II.
Data analysis The approximate EC50 value for the Ang II-potentiating
effect of CsA was 1 mm. Basal 45Ca21 efflux was notResults are presented as the means of several indepen-
dent experiments. Errors are calculated as standard er- significantly changed after preincubation with 0.1 to 10.0
mm CsA.rors of the mean (sem). The unpaired Student’s t-test
was applied to evaluate significance between groups. Angiotensin II acts on vascular SMCs via AT1 recep-
tors, which are coupled to phospholipase C [20]. [Ca21]c
elevation occurs both via inositol 1,4,5-trisphosphate
RESULTS
(IP3)-induced Ca21 mobilization from intracellular stores
Elevation by cyclosporine A of angiotensin II-induced and via Ca21 influx. CsA might elevate the Ang II re-
45Ca21 efflux and [Ca21]c rise sponses by increasing the Ca21 content of intracellular
pools. However, this is not likely to be the case becauseHuman smooth muscle cells (SMCs) were exposed to
1 and 10 mm CsA during 20 to 24 hours, and [Ca21]c no changes in 45Ca21 efflux were observed after inhibition
of the sarcoplasmatic Ca21ATPase by thapsigargin,handling was determined by fura 2 fluorimetry and by
measuring 45Ca21 efflux. Basal [Ca21]c was unaltered by which depletes IP3-sensitive pools (Table 1). In addition,
total cell accumulated 45Ca21 was not changed by CsACsA, whereas increases in the Ca21 responses after stim-
ulation with Ang II were noted (Fig. 1A). The Ang II- (not shown), confirming that CsA did not change the
Ca21 content of intracellular pools.induced [Ca21]c increases over basal levels were 22 6 5
nm for control cells and 51 6 7 and 121 6 25 nm for the The potentiating effects of CsA with respect to re-
sponses to other vasoconstrictor agonists (vasopressincells pretreated with 1 and 10 mm CsA, respectively (Fig.
1B). After preincubation with 10 mm CsA, the difference and ET-1) were also investigated in these human SMCs.
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Table 1. Effect of cyclosporine A on 45Ca21 efflux (% of total cell accumulated 45Ca21 released per minute) in the absence or presence of
angiotensin II (Ang II), endothelin-1 (ET-1), [Arg8]vasopressin (AVP) or thapsigargin (Tg)
Control Cyclosporine A 10 mm Significancea
Basal efflux 2.9560.14 (N523) 3.0160.20 (N513) NS
AngII, 1027 m 4.4960.21 (N526) 7.2360.41 (N528) P,0.001
ET-1, 1027m 13.0860.54 (N53) 12.3760.40 (N53) NS
AVP, 1027m 3.2460.03 (N53) 3.1160.14 (N53) NS
Tg, 1026mb 9.6960.35 (N52) 9.7460.22 (N52) NS
a Significance of the difference of Ang II-induced efflux under control conditions and after pretreatment with CsA
b Thapsigargin was added at 6th minute and 45Ca21 efflux was registered at 9th minute
Preliminary investigations showed that although vaso-
pressin was devoid of a measurable effect, ET-1 strongly
stimulated 45Ca21 efflux, but no potentiation by CsA was
found (Table 1).
Influence of cyclosporine A on angiotensin II
receptors in human smooth muscle cells
The influence of CsA on angiotensin receptors (most
likely AT1 receptors) was studied by [125I]Ang II binding
to these cultured SMCs. After 24 hours of preincubation
with CsA, specific binding was increased by 76 6 25%
(Fig. 3A). An analysis by Scatchard plot showed an ele-
vation in Bmax from 11.9 6 0.7 fmol/mg protein under
control conditions to 21.1 6 0.8 fmol/mg protein after
preincubation with CsA (Fig. 3B). However, CsA did
not change the affinity of AT1 receptors (KD values were Fig. 2. Influence of CsA on angiotensin II (Ang II)-induced increment
1.4 6 0.2 nm and 1.5 6 0.1 nm without or with CsA in 45Ca21 efflux (D 45Ca21). Cells were pretreated for 24 hours with the
indicated concentrations of CsA. The data are normalized to Ang II-preincubation, respectively).
induced increment in 45Ca21 efflux over basal in cells not treated with
CsA. Each point represents the mean 6 sem of three to four experimentsInhibition of cyclosporine A effects on Ca21 fluxes and
performed in quadruplicate. *P , 0.05; **P , 0.02; #P , 0.01. Signifi-
angiotensin II receptors by actinomycin D cance (P values) was determined with respect to control (CT).
Previously published data obtained on rat SMC [14,
21] suggest that stimulation of transcription and protein
synthesis could be involved in the CsA-induced increase
of the Ang II response. As shown in Figure 4, actinomy- Figure 5, CsH also elevated Ang II-induced 45Ca21 efflux,
cin D (1 mm) added together with CsA for 24 hours although to a lesser degree. This indicates that Ca21
suppressed both the CsA-induced Ca21 potentiation and potentiation was produced independently of calcineurin
the increase in specific [125I]Ang II binding. In cells not inhibition.
exposed to CsA, neither the number of Ang II receptors
nor the Ang II-induced 45Ca21 efflux was affected by
DISCUSSIONactinomycin D (Fig. 4).
These results show for the first time, to our knowledge,
The cyclosporine A effect on angiotensin II-induced in human aortic SMCs that CsA at concentrations of 0.1
45Ca21 efflux is independent of calcineurin inhibition to 10.0 mm elevates Ang II-induced [Ca21]c rises and
45Ca21 efflux. The half-maximal effect occurred at ap-The effect of CsA on gene expression in T-lymph-
ocytes is mediated by cyclophilin, which binds to cal- proximately 1 mm, which is close to the plasma concentra-
tion of CsA in patients undergoing immunosuppressivecineurin and suppresses dephosphorylation of the tran-
scription factor NF-AT [1, 2, 22]. To evaluate whether therapy [24, 25]. In parallel, an increase in [125I]Ang II
binding, most likely to the AT1 receptor, was observed.calcineurin inhibition by the CsA-cyclophilin complex is
involved in the CsA effect on Ang II-dependent calcium CsA increased the number of Ang II receptors 1.7-fold
without changing their affinity. Both the effects on recep-regulation in human SMCs, the effects of its closely re-
lated analogue cyclosporine H (CsH), which is not able tor numbers and on [Ca21]c regulation were suppressed
by actinomycin D. These data suggest that CsA enhancesto inhibit calcineurin [23], were studied. As shown in
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Fig. 3. (A) Specific binding of [125I]Ang II
(0.12 nM) to SMCs treated with vehicle or 10
mM CsA for 24 hours (mean 6 SEM of eight
measurements performed in quadruplicate).
(B) Scatchard plot for [125I]Ang II binding to
control (CT; h) and CsA-treated (d) SMCs.
Each point of the plot was obtained from three
to six experiments performed in quadruplicate
(*P , 0.02).
Fig. 4. Influence of actinomycin D (1 mM) on the CsA effects on Ang II-induced 45Ca21 efflux (A) and [125I]Ang II (0.12 nM) binding (B). Data
are mean 6 sem from three experiments performed in quadruplicate. *P , 0.01; **P , 0.05; NS, not significant.
the expression of AT1 receptors in human SMCs by phenomenon of CsA-induced elevation of an agonist
effect occurs in human cells. It is of interest that in humaneither stimulating AT1 receptor mRNA synthesis or in-
creasing its stability. Presumably, the rise of receptor SMCs, the CsA affected only Ang II action with no
change in endothelin-1–induced 45Ca21 efflux (Table 1).numbers caused an increase in the IP3-mediated Ca21
response to Ang II. It is possible that CsA did not influence the expression
of ETA receptors or that the effect of ET-1 on [Ca21]cThis hypothesis is supported by in vivo data. In rats,
CsA administration caused an increase in AT1 receptors was already at a maximal level and therefore could not
be further potentiated.in arterial walls [14]. A CsA-induced elevation of vaso-
constrictor hormone receptors was demonstrated for va- It was demonstrated earlier that CsA is able to in-
crease the filling of intracellular stores with releasablesopressin V1 receptors in cultured SMCs from rat aorta,
an effect that was accompanied by increases in 45Ca21 calcium in hepatocytes [26] and cultured rat aortic SMCs
[15, 27, 28]. In our experiments, no detectable changesefflux, inositol phosphate (IP) formation, and [Ca21]c rise
in response to vasopressin [21]. The responses of these in intracellular 45Ca21 content and in 45Ca21 efflux in
response to the SR-Ca21ATPase inhibitor thapsigarginrat SMCs to ET-1, serotonin, and Ang II were also in-
creased by CsA, as well as the constriction of rat mesen- were noted, indicating that the Ca21 pools were not af-
fected by CsA.teric resistance vessels [16].
These experiments show for the first time that the What is the pathway used by CsA to increase the Ang
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results, indicate the existence of a pathway independent
of cyclophilins.
Unfortunately, there are no in vivo studies regarding
potential nephrotoxic or hypertensive actions of CsH in
humans. However, it has been shown in rats that CsH
does not decrease the glomerular filtration rate after two
weeks of treatment [2]. This apparent nontoxic effect
may be due to the fact the CsH plasma levels in these
experiments were approximately threefold lower than
those of CsA [2].
CsA-induced hypertension and nephrotoxicity [3–5]
are both considered to be initially due to augmentation of
arteriolar contractility [6–9, 27]. Previous investigations
performed on isolated arteries or on vascular SMC have
demonstrated that CsA leads to an increase of the effects
of Ca21-mobilizing hormones, resulting in an increase in
peripheral resistance [15, 16, 21, 27, 28, 36].
Our data suggest that at least one of the mechanisms
by which CsA enhances blood vessel contractility and
blood pressure in humans could be by increasing AT1Fig. 5. Comparison of the effects of CsA and CsH on Ang II-induced
receptors and, therefore, Ang II action. This conclusion45Ca21 efflux. Cells were pretreated with 10 mm CsA or CsH, respectively,
for 24 hours. The data are mean 6 sem from three experiments per- is supported by the fact that CsA-induced increase in
formed in quadruplicate (*P , 0.02; **P , 0.01). arterial blood pressure can be attenuated by inhibitors
of the renin-angiotensin system in combination with cal-
cium antagonists [37, 38].
Similar phenomena might play a role in the develop-
ment of essential hypertension. An increase in the re-II response? The well-known intracellular receptors for
sponse to Ca21-mobilizing agonists has been observedCsA are the cyclophilins [1, 29]. Our data indicate that
on cells from patients with essential hypertension [39]the Ca21 potentiation occurred via a cyclophilin-inde-
or on cells from spontaneously hypertensive rats [40, 41].pendent pathway because CsH, known to have a 1000
In addition, an increase in AT1 receptor density has beentimes lower affinity than CsA to all known cyclophilins
observed in the peripheral tissues of spontaneously hy-[23], was also able to increase Ang II-induced 45Ca21
pertensive rats [11, 12, 42] and in humans with hyperten-efflux, although to a lesser extent. This observation is in
sion [43]. It has been claimed that CsA-induced hyper-accordance with findings on rat SMCs showing that this
tension is similar to some forms of essential hypertensionanalogue also potentiated the Ca21 responses following
[44]. Our data about increases in Ang II-dependent Ca21V1 receptor stimulation [16]. A dissociation between the
regulation induced by CsA in cultured human aorticeffects of CsA on calcium responses and on immunosup-
SMCs, similar to those observed in essential hyperten-pression was first shown in mesangial cells by Goldberg
sion, support such a hypothesis. Further research on theet al [30]. Furthermore, there appears to be a number
mechanisms underlying CsA-induced changes in intra-of effects not likely to be mediated by cyclophilins, as
cellular Ca21 regulation could give insight into the under-they are produced both by CsA and CsH. It is noteworthy
standing of the biochemical basis of some forms of essen-that the relative activities of CsA and CsH are similar
tial hypertension in humans.to those found here. CsH displayed a fourfold lower
potency as CsA in attenuating the interleukin-1b–
induced increase in nitric oxide synthase expression by
ACKNOWLEDGMENTSrenal mesangial cells (IC50 values were 3.6 and 0.9 mm,
This work was supported by grants from Swiss National Sciencerespectively) [31]. Both cyclosporines were shown to in-
Foundation (Nr.7SUPJ048641 and 3100.47294.96), the Russian Foun-hibit the growth of cultured keratinocytes [32, 33] and
dation for Basic Research (Nr.96-04-49921), and the Fondation Herb-
to suppress the effects of phorbol myristate acetate on ette of the University of Lausanne. The authors are grateful to Dr.
E.M. Tararack for providing access to postmortem human material.mouse skin in vivo [34]. CsA or CsH in similar concentra-
We acknowledge the Central laboratory of the Swiss Red Cross founda-tion ranges affected DNA and protein synthesis in the
tion in Berne for the gift of human serum, Drs. H.R. Brunner and J.
renal epithelial cell lines LLC-PK1 and Madin-Darby Nussberger for the gift of [125I]Ang II, and Novartis Pharma for provid-
ing CsA and CsH.canine kidney [35]. Thus, these data, together with our
Avdonin et al: CsA potentiates angiotensin II effects 2413
Reprint requests to Urs T. Ru¨egg, Ph.D., School of Pharmacy, Univer- 20. Corriu C, Andre P, Schott C, Michel M, Stoclet JC: ANG II
sity of Lausanne, CH-1015 Lausanne, Switzerland. receptor expression and function during phenotypic modulation
E-mail: Urs.Ruegg@ict.unil.ch of rat aortic smooth muscle cells. Am J Physiol 266(2 Part 2):H631–
H636, 1994
21. Lo Russo A, Passaquin A-C, Ru¨egg UT: Mechanism of enhanced
vasoconstrictor hormone action in vascular smooth muscle cells
by cyclosporin A. Br J Pharmacol 121:248–252, 1997
REFERENCES 22. McKeon F: When worlds collide: Immunosuppressants meet pro-
tein phosphatases. Cell 66:823–826, 19911. Cardenas ME, Zhu D, Heitman J: Molecular mechanisms of
23. Fliri H, Baumann G, Enz A, Kallen J, Luyten M, Mikol V,immunosuppression by cyclosporine, FK506, and rapamycin. Curr
Movva R, Quesniaux V, Schreier M, Walkinshaw M, Wenger R,Opin Nephrol Hypertens 4:472–477, 1995
Zenke G, Zurini M: Cyclosporins: Structure-activity relationships.2. Borel JF, Baumann G, Chapman I, Donatsch P, Fahr A,
Ann NY Acad Sci 696:47–53, 1993Mueller EA, Vigouret JM: In vivo pharmacological effects of
24. Sturrock ND, Lang CC, Struthers AD: Cyclosporin-inducedciclosporin and some analogues. Adv Pharmacol 35:115–246, 1996
hypertension precedes renal dysfunction and sodium retention in3. Kahan BD: Cyclosporine. N Engl J Med 321:1725–1738, 1989
man. J Hypertens 11:1209–1216, 19934. Skorecki KL, Rutledge WP, Schrier RW: Acute cyclosporine
25. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacoki-nephrotoxicity: Prototype for a renal membrane signaling disorder.
net 24:472–495, 1993Kidney Int 42:1–10, 1992
26. Nicchitta CV, Kamoun M, Williamson JR: Cyclosporine aug-5. Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz
ments receptor-mediated cellular Ca21 fluxes in isolated hepato-LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom
cytes. J Biol Chem 260:13613–13618, 1985RA, Burnett JC: Cyclosporine-induced hypertension after trans-
27. Rego A, Vargas R, Suarez KR, Foegh ML, Ramwell PW: Mech-plantation. Mayo Clin Proc 69:1182–1193, 1994
anism of cyclosporin potentiation of vasoconstriction of the isolated6. Xue H, Bukoski RD, McCarron DA, Bennett WM: Induction
rat mesenteric arterial bed: Role of extracellular calcium. J Phar-of contraction in isolated rat aorta by cyclosporine. Transplantation
macol Exp Ther 254:799–808, 199043:715–718, 1987
28. Meyer-Lehnert H, Bokemeyer D, Friedrichs U, Backer A,7. Lamb FS, Webb RC: Cyclosporine augments reactivity of isolated
Kramer HJ: Cellular mechanisms of cyclosporine A-associatedblood vessels. Life Sci 40:2571–2578, 1987
side-effects: Role of endothelin. Kidney Int 52(Suppl 61):S27–S31,8. Kaye D, Thompson J, Jennings G, Esler M: Cyclosporine therapy
1997after cardiac transplantation causes hypertension and renal vaso-
29. Handschumacher RE, Harding MW, Rice J, Drugge RJ,constriction without sympathetic activation. Circulation 88:1101–
Speicher DW: Cyclophilin: A specific cytosolic binding protein for1109, 1993
cyclosporin A. Science 226:544–547, 19849. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM:
30. Goldberg HJ, Wong PY, Cole EH, Levy GA, Skorecki KL:Vascular mechanisms of cyclosporin-induced hypertension in the
Dissociation between the immunosuppressive activity of cyclo-rat. J Clin Invest 93:2244–2250, 1994
sporine derivatives and their effects on intracellular calcium signal-10. Ferrario CM: Importance of the renin-angiotensin-aldosterone
ing in mesangial cells. Transplantation 47:731–733, 1989system (RAS) in the physiology and pathology of hypertension:
31. Muhl H, Kunz D, Rob P, Pfeilschifter J: Cyclosporin derivativesAn overview. Drugs 39(Suppl 2):1–8, 1990
inhibit interleukin 1-beta induction of nitric oxide synthase in renal11. Haws RM, Shaul PW, Arant BS Jr, Atiyeh BA, Seikaly MG:
cells. Eur J Pharmacol 249:95–100, 1993Glomerular losartan (DuP 753)-sensitive angiotensin II receptor
32. Ramirez-Bosca A, Kanitakis J, Haftek M, Faure M, Castells-density is increased in young spontaneously hypertensive rats. Pedi-
Rodellas A, Thivolet J: Nonimmunosuppressive cyclosporin Hatr Res 35:671–676, 1994
inhibits the growth and DNA synthesis of cultured normal human12. Wu JN, Edwards D, Berecek KH: Changes in renal angiotensin
epidermal keratinocytes. Skin Pharmacol 2:175–179, 1989II receptors in spontaneously hypertensive rats by early treatment
33. Amsellem C, Haftek M, Kanitakis J, Thivolet J: Effect ofwith the angiotensin-converting enzyme inhibitor captopril. Hyper-
cyclosporins A, G, and H on normal and ichthyotic keratinocytetension 23(6 Part 2):819–822, 1994
growth in culture. Arch Dermatol Res 284:173–178, 199213. Sato A, Suzuki H, Nakazato Y, Shibata H, Inagami T, Saruta
34. Gschwendt M, Kittstein W, Marks F: The weak immunosup-T: Increased expression of vascular angiotensin II type 1A recep-
pressant cyclosporine D as well as the immunologically inactivetor gene in glucocorticoid-induced hypertension. J Hypertension
cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-12:511–516, 1994
induced biological effects in mouse skin and of Ca21/calmodulin14. Iwai J, Kanayama Y, Negoro N, Inoue T, Okamura M, Takeda
dependent EF-2 phosphorylation in vitro. Biochem Biophys ResT: Increased gene expression of angiotensin II type 1A receptor
Commun 150:545–551, 1988in aortic smooth muscle cells of cyclosporin A-induced hyperten-
35. Walker RJ, Lazzaro VA, Duggin GG, Horvath JS, Tiller DJ:sive rats. J Hypertens 11(Suppl 5):S122–S123, 1993
Structure-activity relationships of cyclosporines: Toxicity in cul-15. Pfeilschifter J, Ruegg UT: Cyclosporin A augments angiotensin
tured renal tubular epithelial cells. Transplantation 48:321–327,II-stimulated rise in intracellular free calcium in vascular smooth
1989muscle cells. Biochem J 248:883–887, 1987
36. Meyer-Lehnert H, Schrier RW: Potential mechanism of cyclo-16. Lo Russo A, Passaquin AC, Andre´ P, Skutella M, Ruegg UT:
sporine A-induced vascular smooth muscle contraction. Hyperten-Effect of cyclosporin A and analogues on cytosolic calcium and
sion 13:352–360, 1989vasoconstriction: Possible lack of relationship to immunosuppres-
37. Hartmann A, Schweitzer G, Stratmann D, Kaltenbach M,sive activity. Br J Pharmacol 118:885–892, 1996
Kober G: Effects of nitrendipine and lisinopril on blood pressure17. Orekhov AN, Kosykh VA, Repin VS, Smirnov VN: Cell prolifera-
and sodium excretion in cyclosporin-associated hypertension aftertion in normal and atherosclerotic human aorta. I. Flow cytofluor-
heart transplantation. Cardiology 83:141–149, 1993ometric determination of cellular deoxyribonucleic acid content.
38. Mimran A, Ribstein J: Angiotensin-converting enzyme inhibitorsLab Invest 48:395–398, 1983
versus calcium antagonists in the progression of renal diseases.18. Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca21
Am J Hypertension 7(9 Part 2):73S–81S, 1994indicators with greatly improved fluorescence properties. J Biol
39. Shkhvatsabaia IK, Kravchenko AN, Avdonin PV, Men’shikovChem 260:3440–3450, 1985
MI, Nekrasova AA: Receptor-dependent regulation of the con-19. Bradford M: A rapid and sensitive method for the quantitation
centration of Ca21 in the cytoplasm of thrombocytes in hyperten-of microgram quantities of protein utilizing the principle of protein-
dye binding. Anal Biochem 72:248–254, 1976 sive patients. Kardiologiia 28:72–77, 1988
Avdonin et al: CsA potentiates angiotensin II effects2414
40. Orlov SN, Pokudin NI, Postnov IV: Intracellular concentration K, Miyazaki M: Mapping of angiotensin II receptor subtypes in
peripheral tissues of spontaneously hypertensive rats by in vitroof free calcium in thrombocytes: Its characteristics in spontaneous
hypertension. Kardiologiia 24:93–98, 1984 autoradiography. Clin Exp Pharmacol Physiol (Suppl 1):S17–S19,
199541. Cortes SF, Lemos VS, Corriu C, Stoclet JC: Changes in angioten-
sin II receptor density and calcium handling during proliferation 43. Brown L, Sernia C: Angiotensin receptors in cardiovascular dis-
eases. Clin Exp Pharmacol Physiol 21:811–818, 1994in SHR aortic myocytes. Am J Physiol 271(6 Part 2):H2330–H2338,
1996 44. Luke RG: Essential hypertension: A renal disease? A review and
update of the evidence. Hypertension 21:380–390, 199342. Song K, Kurobe Y, Kanehara H, Wada T, Inada Y, Nishikawa
